A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer

A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer

Abstract Increasing evidence suggests that antibody-drug conjugates (ADCs) can enhance anti-tumor immunity and improve clinical outcome. Here, we elucidate the therapeutic efficacy and immune-mediated mechanisms of a novel HER2-targeting ADC bearing a potent anthracycline derivate as payload (T-PNU)...

Full description

Bibliographic Details
Main Authors: Lucia D’Amico, Ulrike Menzel, Michael Prummer, Philipp Müller, Mélanie Buchi, Abhishek Kashyap, Ulrike Haessler, Alexander Yermanos, Rémy Gébleux, Manfred Briendl, Tamara Hell, Fabian I. Wolter, Roger R. Beerli, Iva Truxova, Špíšek Radek, Tatjana Vlajnic, Ulf Grawunder, Sai Reddy, Alfred Zippelius
Format: Article
Language:English
Published: BMJ Publishing Group 2019-01-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Antibody-drug conjugates
HER2-positive breast cancer
Anthracycline
Checkpoint inhibitor combination therapy
Online Access:http://link.springer.com/article/10.1186/s40425-018-0464-1

Internet

http://link.springer.com/article/10.1186/s40425-018-0464-1

Similar Items